Literature DB >> 2863272

Prolactin-inducible proteins in human breast cancer cells.

R P Shiu, B M Iwasiow.   

Abstract

The mechanism of action of prolactin in target cells and the role of prolactin in human breast cancer are poorly understood phenomena. The present study examines the effect of human prolactin (hPRL) on the synthesis of unique proteins by a human breast cancer cell line, T-47D, in serum-free medium containing bovine serum albumin. [35S]Methionine-labeled proteins were analysed by sodium dodecyl sulfate-polyacrylamide slab gel electrophoresis and fluorography. Treatment of cells with hPRL (1-1000 ng/ml) and hydrocortisone (1 microgram/ml) for 36 h or longer resulted in the synthesis and secretion of three proteins having molecular weights of 11,000, 14,000, and 16,000. Neither hPRL nor hydrocortisone alone induced these proteins. Of several other peptide hormones tested, only human growth hormone, a hormone structurally and functionally similar to hPRL, could replace hPRL in causing protein induction. These three proteins were, therefore, referred to as prolactin-inducible proteins (PIP). Each of the three PIPs was purified to homogeneity by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and specific antibodies were generated to them in rabbits. By immunoprecipitation and immunoblotting (Western blot) of proteins secreted by T-47D cells, it was demonstrated that the three PIPs were immunologically identical to one another. In addition, the 16-kDa and 14-kDa proteins (PIP-16 and PIP-14), and not the 11-kDa protein (PIP-11), incorporated [3H]glycosamine. Furthermore, 2-deoxyglucose (2 mM) and tunicamycin (0.5 micrograms/ml), two compounds known to inhibit glycosylation, blocked the production of PIP-16 and PIP-14, with a concomitant increase in the accumulation of PIP-11. These results indicate PIP-16 and PIP-14 are glycosylated variants of PIP-11. Finally, in vitro translation of poly(A)+ messenger RNA followed by immunoprecipitation revealed a 12.5-kDa protein, possibly the precursor form of PIPs. In addition, T-47D cells treated with hPRL plus hydrocortisone contained 10-fold more mRNA for PIPs than control cells, suggesting that the hormones' action is at the level of gene expression. Our finding represents a first demonstration of prolactin regulation of gene expression in human target cells. The human breast cancer cells, T-47D, appear to be an excellent model to afford future studies on the molecular action of prolactin and on the possible role of prolactin in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863272

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple LewisY epitopes generate highly-fucosylated glycan structures.

Authors:  Alena Wiegandt; Henning N Behnken; Bernd Meyer
Journal:  Glycoconj J       Date:  2018-06-01       Impact factor: 2.916

Review 2.  Morphological, hormonal, and molecular changes in different maternal tissues during lactation and post-lactation.

Authors:  Gustavo Canul-Medina; Cristina Fernandez-Mejia
Journal:  J Physiol Sci       Date:  2019-09-28       Impact factor: 2.781

Review 3.  The enigmatic nature of apocrine breast lesions.

Authors:  P Zagorianakou; N Zagorianakou; D Stefanou; G Makrydimas; N J Agnantis
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

4.  Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.

Authors:  Sanjeev K Baniwal; Gillian H Little; Nyam-Osor Chimge; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

Review 5.  Prolactin as an autocrine/paracrine factor in breast tissue.

Authors:  C V Clevenger; T L Plank
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

6.  Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues.

Authors:  M Ben-David; T Kadar; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

Authors:  L De Petrocellis; D Melck; A Palmisano; T Bisogno; C Laezza; M Bifulco; V Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.

Authors:  Karolina Jablonska; Jedrzej Grzegrzolka; Marzenna Podhorska-Okolow; Mariusz Stasiolek; Bartosz Pula; Mateusz Olbromski; Agnieszka Gomulkiewicz; Aleksandra Piotrowska; Janusz Rys; Aleksandra Ambicka; Siew Hwa Ong; Maciej Zabel; Piotr Dziegiel
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

9.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop.

Authors:  C V Clevenger; W P Chang; W Ngo; T L Pasha; K T Montone; J E Tomaszewski
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

10.  Downregulation of Prolactin-Induced Protein Promotes Osteogenic Differentiation of Periodontal Ligament Stem Cells.

Authors:  Xiaomeng Li; Yunpeng Zhang; Linglu Jia; Yixiao Xing; Bin Zhao; Lei Sui; Dayong Liu; Xin Xu
Journal:  Med Sci Monit       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.